AMENDMENTS TO THE CLAIMS

Claim 1 (Previously presented):   An isolated human antibody that specifically binds to ~~an epitope specifically bound by an antibody expressed by~~ clone huC25, , wherein said antibody binds to and ~~neutralizes~~ botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO:87), VH CDR2 (SEQ ID NO:89), and VH CDR3 (SEQ ID NO:127).

Claims 2-16 (Canceled).

Claim 17 (Currently amended):   An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO:157), VL CDR2 (SEQ ID NO:159), and VL CDR3 (SEQ ID NO:197). ~~The antibody of claim 1, wherein said antibody comprises at least two variable heavy (V$_H$) complementarity determining regions (CDRs) of huC25.~~

Claim 18 (Currently amended):   An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody further comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO:87), VH CDR2 (SEQ ID NO:89), and VH CDR3 (SEQ ID NO:127); and a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO:157), VL CDR2 (SEQ ID NO:159), and VL CDR3 (SEQ ID NO:197). ~~The antibody of claim 17, wherein said antibody comprises at three variable heavy (V$_H$) complementarity determining regions (CDRs) of HuC25.~~

Claims 19-22.

Claim 23 (Currently amended):   The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is a single chain Fv (scFv).

Claim 24 (Currently amended):   The antibody of ~~any one of claims 1, 17, or 18, claim 1,~~ wherein said antibody is an IgG.

Claim 25 (Currently amended):   The antibody of ~~any one of claims 1, 17, or 18, claim 1,~~ wherein said antibody is a Fab.

Claim 26 (Currently amended):   The antibody of ~~any one of claims 1, 17, or 18, claim 1,~~wherein said antibody is a (Fab')$_2$.

Claim 27 (Currently amended):   The antibody of ~~any one of claims 1, 17, or 18, claim 1,~~wherein said antibody is a (scFv')$_2$.

Claim 28 (Original):   The antibody of claim 27, wherein said antibody is a fusion protein of two scFv fragments.

Claim 29 (Currently amended):   The antibody of claim 1, wherein said antibody comprises ~~a~~ the heavy variable framework region of huC25.

Claim 30 (Currently amended):   The antibody of claim ~~29~~17, wherein said ~~antibody comprises the light variable framework region~~ ~~framework is a variable heavy (V$_H$) framework~~ of huC25.

Claim 31 (Currently amended):   The antibody of claim 1, wherein said antibody comprises a variable heavy region of huC25.~~29, wherein said framework is a variable light (V$_L$) framework of huC25.~~

Claim 32 (Currently amended):   The antibody of claim 17, wherein said antibody comprises the variable light region of huC25.~~30, wherein said antibody comprises at least two variable heavy (V$_H$) framework regions of huC25.~~

Claim 33 (Currently amended):   The antibody of claim 18, wherein said antibody comprises the variable heavy region of huC25 and the variable light region of huC25.~~31, wherein said antibody comprises at least two variable light (V$_L$) framework regions of huC25.~~

Claims 34 (Currently amended): The antibody of claim <u>18, wherein said antibody comprises the amino acid sequence of huC25 scFv.</u>~~30, wherein said antibody comprises a variable heavy (V~~<u>H</u>~~) region of huC25.~~

Claims 35-115 (Canceled).

Claim 116 (Currently amended): A composition comprising a plurality of anti-botulinum neurotoxin antibodies, wherein each <u>species of</u> antibody is specific for a different epitope of a botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality<u>, and wherein said composition comprises an antibody according to any one of claims 1, 17, or 18</u>.

Claim 117 (Original): The composition of claim 116, wherein said composition comprises a first antibody that binds and neutralizes an A1 toxin and a second antibody that binds and neutralizes an A2 toxin.

Claim 118 (Canceled).